Shandong Luoxin Pharmaceutical Group Stock Co., Ltd (SHE: 002793), a pharmaceutical company based in China, has entered into a strategic partnership with Xbiome, a compatriot firm specializing in AI-based microbiome drug development. This collaboration grants Luoxin access to Xbiome’s advanced intestinal microbiota transplantation medical technology, marking a significant step in the field of microbiome-based therapies.
Under the terms of the agreement, the two companies will engage in commercial cooperation within the specified cooperation area and channel scope. While the financial details and specific aspects of the deal remain undisclosed, this partnership signals a commitment to leveraging AI-driven microbiome technologies for the development and commercialization of innovative medical solutions.- Flcube.com
